<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451916</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-HF-01</org_study_id>
    <nct_id>NCT03451916</nct_id>
  </id_info>
  <brief_title>Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)</brief_title>
  <official_title>Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD&#xD;
      intramuscular administration for the treatment of muscle injury following arthroplasty for&#xD;
      HF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, multinational, randomized, double-blind, placebo-controlled study,&#xD;
      assessing the efficacy, safety, and tolerability of intramuscular (IM) administration of&#xD;
      allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for HF as&#xD;
      compared to placebo treatment. Both treatment arms will receive standard of care treatment&#xD;
      per local practice.&#xD;
&#xD;
      The study will comprise 2 periods:&#xD;
&#xD;
        1. Main study period - from Screening to 52 weeks post-treatment. During this period, the&#xD;
           subjects will have the following study visits: Screening, Day 0 (treatment and surgery&#xD;
           day), Day 1, Day 5, Week 6, Week 12, Week 26 and Week 52.&#xD;
&#xD;
        2. Safety follow-up period - from Week 52 to Week 104. During this safety follow-up period,&#xD;
           there will be a phone call visit at Week 104 and Only survival and quality of life data,&#xD;
           serious adverse events (SAEs) and new malignancy adverse events will be collected.&#xD;
&#xD;
      The main study period will comprise 4 periods:&#xD;
&#xD;
        1. Screening and pre-surgery time&#xD;
&#xD;
        2. Surgery and treatment with PLX-PAD or placebo (Day 0)&#xD;
&#xD;
        3. Hospital follow-up until Day 5±1, at least&#xD;
&#xD;
        4. Follow-up period up to 52 weeks following study treatment administration. Subjects will&#xD;
           be assessed for study eligibility before the emergency surgery for HF. After being found&#xD;
           eligible, subjects will be randomized using a 1:1 allocation scheme to either 150×106&#xD;
           PLX-PAD cells or to placebo treatment, respectively. Within 48 hours of admission and up&#xD;
           to 72 hours following fracture, subjects will undergo HA or THA. During the surgical&#xD;
           procedure, the subjects will receive the investigational product in accordance with the&#xD;
           treatment group to which they were randomized. Thereafter, visits will be conducted at&#xD;
           Days 1 and 5±1, and at Weeks 6, 12, 26, 52 and 104.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>, subjects will be randomized using a 1:1 allocation scheme to either 150×10^6 PLX-PAD cells or to placebo treatment, respectively</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Physical Performance Battery (SPPB) score</measure>
    <time_frame>Week 26.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hip abduction strength of the injured leg</measure>
    <time_frame>Week 26.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 52 in lower extremity measure (LEM) (retrospective collection of pre-fracture LEM at Day 5±1).</measure>
    <time_frame>baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPPB score</measure>
    <time_frame>Week 52.</time_frame>
    <description>The Short Physical Performance Battery (SPPB) is an objective assessment tool for evaluating lower extremities function. The SPPB consists of 3 types of physical maneuvers: balance test, speed gait test, and chair stand test. Results from each maneuvers test are scored on a scale of 0 to 4, with an increasing composite score indicating an improved lower extremities function level. The total maximum score of SPPB is 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>PLX-PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm 1 - PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX-PAD</intervention_name>
    <description>PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte</description>
    <arm_group_label>PLX-PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects&#xD;
&#xD;
          2. Subjects up to 90 years of age, inclusive, at the time of Screening&#xD;
&#xD;
          3. Subjects suffering low energy trauma with intracapsular neck of femur fracture.&#xD;
&#xD;
          4. Planned to be treated with total hip arthroplasty (THA) or hemi-arthroplasty (HA)&#xD;
             within 48 hours of hospital admission and 72 hours post fracture.&#xD;
&#xD;
          5. Subjects able to walk 10 feet/3 meters before the fracture.&#xD;
&#xD;
          6. Signed an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Any significant musculoskeletal, neurologic or neuromuscular disease causing muscle&#xD;
             weakness and/or affecting mobility 2. Current fracture is due to bone pathology other&#xD;
             than osteoporosis or due to major trauma 3. Planned orthopedic surgery on lower limbs&#xD;
             (excluding hip arthroplasty) within the next 12 months.&#xD;
&#xD;
             4. Diabetes mellitus with HbA1c &gt;10% at Screening. 5. Known current or history of&#xD;
             proliferative retinopathy or diabetic retinopathy.&#xD;
&#xD;
             6. Known active Hepatitis B virus or Hepatitis C virus infection. 7. Known human&#xD;
             immunodeficiency virus (HIV) infection, severe uncontrolled inflammatory disease or&#xD;
             severe uncontrolled autoimmune disease (e.g., ulcerative colitis, Crohn's disease,&#xD;
             etc).&#xD;
&#xD;
             8. Subjects on renal replacement therapy or with estimated glomerular filtration rate&#xD;
             (eGFR) &lt;15 mL/min/1.73m2 9. Severe congestive heart failure symptoms (New York Heart&#xD;
             Association [NYHA] Stage IV).&#xD;
&#xD;
             10. Known uncontrolled severe hypertension. 11. Treatment with anabolic steroids&#xD;
             within 6 months prior to study start 12. Active malignancy or history of malignancy&#xD;
             within 3 years prior to study start 13. Known moderate to severe dementia or severe&#xD;
             psychiatric disorder. 14. Known allergies to any of the following: dimethyl sulfoxide&#xD;
             (DMSO), human serum albumin (HSA), bovine serum albumin, PlasmaLyte.&#xD;
&#xD;
             15. History of allergic/hypersensitivity reaction to any substance having required&#xD;
             hospitalization and/or treatment with IV steroids/epinephrine 16. Pulmonary disease&#xD;
             requiring supplemental oxygen treatment on a daily basis. 17. life expectancy of less&#xD;
             than 6 months, for reasons other than HF complications, 18. Subject is currently&#xD;
             enrolled in or has not yet completed a period of at least 30 days since ending other&#xD;
             investigational device or drug trial(s).&#xD;
&#xD;
             19. In the opinion of the Investigator, the subject is unsuitable for participating in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Of California Davis,4860 Y Street</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A Lee, Dr.</last_name>
      <phone>916-734-2729</phone>
      <email>marlee@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Mark A Lee, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Metro Orthopedics, P.C. 499 E. Hampden Avenue, Suite 140 Englewood, CO 80113</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Schwappach, Dr</last_name>
      <phone>303-789-3000</phone>
      <email>schwappach@dmortho.com</email>
    </contact>
    <investigator>
      <last_name>John Schwappach, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ANTRIA, INC,300 Indian Springs Road,Indiana</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bizousky, Dr.</last_name>
      <phone>724-349-0520</phone>
      <email>DBIZOUSKY@ANTRIA.ORG</email>
    </contact>
    <investigator>
      <last_name>David Bizousky, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Ljulin&quot; Department of Orthopedy and Traumatology</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plamen a Gurov</last_name>
      <phone>+359887261373</phone>
      <email>gurov@resbiomed.com</email>
    </contact>
    <investigator>
      <last_name>Ivelin Kostadinov, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Serdika&quot; Department of Orthopedy and Traumatology</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plamen Gurov</last_name>
      <phone>+359 88 726 1373</phone>
      <email>gurov@resbiomed.com</email>
    </contact>
    <investigator>
      <last_name>Nikolay Tivchev, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plamen a Gurov</last_name>
      <phone>+35988726137</phone>
      <email>gurov@resbiomed.com</email>
    </contact>
    <investigator>
      <last_name>Nedelcho Tzachev, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment in Orthopedy</name>
      <address>
        <city>Sofia</city>
        <zip>1614</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plamen a Gurov</last_name>
      <phone>+35988726137</phone>
      <email>gurov@resbiomed.com</email>
    </contact>
    <investigator>
      <last_name>Andrey Andreev, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Mitte,Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Zergiebel</last_name>
      <phone>+49 30 450 515 235</phone>
      <email>Anne.Zergiebel@charite.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Winkler, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea Redemann</last_name>
      <phone>+49 351 458 12768</phone>
      <email>dorothea.redemann@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Klaus D Schaser, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Laumann</last_name>
      <phone>0152 54955938</phone>
      <email>marion.laumann@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Richard Stange, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center,7 Michal St</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Bernfeld, Dr.</last_name>
      <phone>+972-544988926</phone>
      <email>bernfeld_benny@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Benjamin Bernfeld, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center,The Orthopedic Department,Shmu'el Bait St. 12</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Toybenshlak, Dr.</last_name>
      <phone>+972-2-6555566</phone>
      <email>michaelt@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Michael Toybenshlak, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center-Internal Medicine E;59 Tshernichovsky Street</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaron Brin, Dr.</last_name>
      <phone>+972-9-7471746</phone>
      <email>yaronbrin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yaron Brin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center,Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Avivi, Dr.</last_name>
      <phone>+972-3-5302417</phone>
      <email>eran.avivi@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Eran Avivi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center,Pasternak St., P.O.B 1,Rehovot</name>
      <address>
        <city>Reẖovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yona Kosashvili, Prof</last_name>
      <phone>1 972523277422</phone>
      <email>Yonako1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yona Kosashvili, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center,6 Weizmann St; Harrison Building 6 Floor</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Salai, Prof.</last_name>
      <phone>97236974720</phone>
      <email>moshesa@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Salai, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lewis</last_name>
      <phone>+441865 223108</phone>
      <email>Kathryn.Lewis@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jowan Penn-Barwell, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

